| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.
|
Blood
|
2005
|
4.29
|
|
2
|
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
|
Arthritis Rheum
|
2003
|
3.29
|
|
3
|
Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
|
Arthritis Rheum
|
2009
|
1.51
|
|
4
|
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
|
Rheumatology (Oxford)
|
2010
|
1.08
|
|
5
|
Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression.
|
J Immunol
|
2008
|
1.08
|
|
6
|
Flavonoids and related compounds as anti-allergic substances.
|
Allergol Int
|
2007
|
1.07
|
|
7
|
Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica.
|
J Rheumatol
|
2010
|
0.98
|
|
8
|
A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
|
Mod Rheumatol
|
2011
|
0.96
|
|
9
|
Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.
|
Ann Rheum Dis
|
2010
|
0.94
|
|
10
|
Viral load of human herpesvirus 8 (HHV-8) in the circulatory blood cells correlates with clinical progression in a patient with HHV-8-associated solid lymphoma with aids-associated Kaposi's sarcoma.
|
Leuk Lymphoma
|
2004
|
0.89
|
|
11
|
Therapeutic effect of tocilizumab on two patients with polymyositis.
|
Rheumatology (Oxford)
|
2011
|
0.88
|
|
12
|
Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction.
|
PLoS One
|
2013
|
0.85
|
|
13
|
Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.
|
Mod Rheumatol
|
2009
|
0.83
|
|
14
|
Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis.
|
Joint Bone Spine
|
2008
|
0.80
|
|
15
|
Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens.
|
Mod Rheumatol
|
2009
|
0.79
|
|
16
|
Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis.
|
Proteomics Clin Appl
|
2007
|
0.78
|
|
17
|
Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis.
|
Allergol Int
|
2009
|
0.77
|
|
18
|
Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
|
Mod Rheumatol
|
2014
|
0.77
|
|
19
|
Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab.
|
Mod Rheumatol
|
2011
|
0.77
|
|
20
|
What kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et al.
|
Arthritis Rheum
|
2008
|
0.75
|
|
21
|
Effect of enzymatically modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-controlled trial.
|
Int Arch Allergy Immunol
|
2009
|
0.75
|
|
22
|
Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
|
Rheumatology (Oxford)
|
2009
|
0.75
|
|
23
|
Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
|
Digestion
|
2014
|
0.75
|